We are an entrepreneurial pharmaceutical company focused on creating
medicines that make a difference for patients, building value to earn the
continued support of our fellow shareholders, and empowering our team to
passionately pursue excellence. If we do these things well, we hope to earn the
right to continue doing them and, one step at a time, build an enduring
pharmaceutical company that helps patients lead better lives.
Our core strategy is to establish a leading gastrointestinal, or GI,
therapeutics company, leveraging our development and commercial capabilities in
addressing GI disorders as well as our pharmacologic expertise in guanylate
cyclase, or GC, pathways. This expertise is based on our work advancing our lead
product, linaclotide, which is the first, and to date, only product approved by
the U.S. Food and Drug Administration, or FDA, in a new class of GI medicines
called guanylate cyclase type-C, or GC-C, agonists.